Pentoxifylline aggravates fatty liver in obese and diabetic ob/ob mice by increasing intestinal glucose absorption and activating hepatic lipogenesis

British Journal of Pharmacology

Volumn 165, Issue 5, 2012, Pages 1361-1374

  Massart, J ^a   Robin, M A ^a   Noury, F ^b   Fautrel, A ^a,c   Letteron P ^d   Bado, A ^d   Eliat, P A ^b   Fromenty, B ^a  

^a INSERM   (France)

^b UNIVERSITÉ DE RENNES 1   (France)

^c IFR 140   (France)

^d CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

Author keywords

ChREBP; drug induced liver injury; fatty liver; glucose; methylxanthine; obesity; pentoxifylline

Indexed keywords

3 HYDROXYBUTYRIC ACID; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CARBOHYDRATE RESPONSE ELEMENT BINDING PROTEIN; GLUCOSE; GLUCOSE TRANSPORTER 2; GLYCEROL; INSULIN; LIPID; PENTOXIFYLLINE; SODIUM GLUCOSE COTRANSPORTER 1; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRANSCRIPTION FACTOR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY FAT; BODY MASS; CONTROLLED STUDY; DIABETES MELLITUS; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; FATTY ACID OXIDATION; FATTY LIVER; GLUCOSE ABSORPTION; GLYCOLYSIS; HISTOPATHOLOGY; HYPERGLYCEMIA; HYPOTRIGLYCERIDEMIA; IN VIVO STUDY; INFLAMMATION; JEJUNUM; LEAN BODY WEIGHT; LIPID STORAGE; LIPOGENESIS; LIVER FUNCTION; LIVER WEIGHT; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OBESITY; ORAL GLUCOSE TOLERANCE TEST; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK REDUCTION; TREATMENT DURATION; WEIGHT GAIN; WESTERN BLOTTING;

ADIPOCYTES; ANIMALS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CELL LINE, TUMOR; DIABETES MELLITUS, TYPE 2; FATTY LIVER; GLUCOSE; GLUCOSE TOLERANCE TEST; GLUCOSE TRANSPORTER TYPE 2; GLYCOLYSIS; HUMANS; INFLAMMATION; INTESTINAL ABSORPTION; JEJUNUM; LIPIDS; LIPOGENESIS; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, OBESE; NUCLEAR PROTEINS; OBESITY; OXIDATIVE STRESS; PENTOXIFYLLINE; SODIUM-GLUCOSE TRANSPORTER 1; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRANSAMINASES; TRANSCRIPTION FACTORS; TRIGLYCERIDES;

EID: 84857097628     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01580.x     Document Type: Article

References (58)

1. Adams LA, Zein CO, Angulo P, Lindor KD, (2004). A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am J Gastroenterol 99: 2365-2368.
2. Andrikopoulos S, Blair AR, Deluca N, Fam BC, Proietto J, (2008). Evaluating the glucose tolerance test in mice. Am J Physiol Endocrinol Metab 295: E1323-E1332.
3. Bartels ED, Lauritsen M, Nielsen LB, (2002). Hepatic expression of microsomal triglyceride transfer protein and in vivo secretion of triglyceride-rich lipoproteins are increased in obese diabetic mice. Diabetes 51: 1233-1239.
4. Beermann B, Ings R, Mansby J, Chamberlain J, McDonald A, (1985). Kinetics of intravenous and oral pentoxifylline in healthy subjects. Clin Pharmacol Ther 37: 25-28.
5. Begriche K, Igoudjil A, Pessayre D, Fromenty B, (2006). Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion 6: 1-28.
6. Begriche K, Lettéron P, Abbey-Toby A, Vadrot N, Robin MA, Bado A, et al,. (2008a). Partial leptin deficiency favors diet-induced obesity and related metabolic disorders in mice. Am J Physiol Endocrinol Metab 294: E939-E951.
7. Begriche K, Massart J, Abbey-Toby A, Igoudjil A, Lettéron P, Fromenty B, (2008b). β-aminoisobutyric acid prevents diet-induced obesity in mice with partial leptin deficiency. Obesity 16: 2053-2067.
8. Begriche K, Knockaert L, Massart J, Robin MA, Fromenty B, (2009). Mitochondrial dysfunction in nonalcoholic steatohepatitis (NASH): are there drugs able to improve it ? Drug Discov Today Dis Mech 6: e11-e23.
9. Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R, (2004). Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs. Gastroenterol Clin Biol 28: 720-759.
10. Bottomley PA, (1987). Spatial localization in NMR spectroscopy in vivo. Ann N Y Acad Sci 508: 333-348.
11. Buettner R, Schölmerich J, Bollheimer LC, (2007). High-fat diets: modeling the metabolic disorders of human obesity in rodents. Obesity 15: 798-808.
12. Burcelin R, Crivelli V, Dacosta A, Roy-Tirelli A, Thorens B, (2002). Heterogeneous metabolic adaptation of C57BL/6J mice to high-fat diet. Am J Physiol Endocrinol Metab 282: E834-E842.
13. Cazanave SC, Mott JL, Elmi NA, Bronk SF, Werneburg NW, Akazawa Y, et al,. (2009). JNK1-dependent PUMA expression contributes to hepatocyte lipoapoptosis. J Biol Chem 284: 26591-26602.
14. Cerec V, Glaise D, Garnier D, Morosan S, Turlin B, Drenou B, et al,. (2007). Transdifferentiation of hepatocyte-like cells from the human hepatoma HepaRG cell line through bipotent progenitor. Hepatology 45: 957-967.
15. Chan MY, Zhao Y, Heng CK, (2008). Sequential responses to high-fat and high-calorie feeding in an obese mouse model. Obesity 16: 972-978.
16. Choi SS, Diehl AM, (2008). Hepatic triglyceride synthesis and non-alcoholic fatty liver injury. Curr Opin Lipidol 19: 295-300.
17. Dallas C, Gerbi A, Tenca G, Juchaux F, Bernard FX, (2008). Lipolytic effect of a polyphenolic citrus dry extract of red orange, grapefruit, orange (SINETROL) in human body fat adipocytes. Mechanism of action by inhibition of cAMP-phosphodiesterase (PDE). Phytomedicine 15: 783-792.
18. Delgado TC, Pinheiro D, Caldeira M, Castro MM, Geraldes CF, Lõpez-Larrubia P, et al,. (2009). Sources of hepatic triglyceride accumulation during high-fat feeding in the healthy rat. NMR Biomed 22: 310-317.
19. Dentin R, Benhamed F, Pégorier JP, Foufelle F, Viollet B, Vaulont S, et al,. (2005). Polyunsaturated fatty acids suppress glycolytic and lipogenic genes through the inhibition of ChREBP nuclear protein translocation. J Clin Invest 115: 2843-2854.
20. Dumont J, Jossé R, Lambert C, Anthérieu S, Le Hegarat L, Aninat C, et al,. (2010). Differential toxicity of heterocyclic aromatic amines and their mixture in metabolically competent HepaRG cells. Toxicol Appl Pharmacol 245: 256-263.
21. Fabbrini E, Sullivan S, Klein S, (2010). Obesity and nonalcoholic fatty liver disease: biochemical, metabolic and clinical implications. Hepatology 51: 679-689.
22. Farrell GC, Larter CZ, (2006). Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43 (2 Suppl 1): S99-S112.
23. Ferber S, Meyerovitch J, Kriauciunas KM, Kahn CR, (1994). Vanadate normalizes hyperglycemia and phosphoenolpyruvate carboxykinase mRNA levels in ob/ob mice. Metabolism 43: 1346-1354.
24. Fromenty B, Vadrot N, Massart J, Turlin B, Barri-Ova N, Lettéron P, et al,. (2009). Chronic ethanol consumption lessens the gain of body weight, liver triglycerides, and diabetes in obese ob/ob mice. J Pharmacol Exp Ther 331: 23-34.
25. He Z, Jiang T, Wang Z, Levi M, Li J, (2004). Modulation of carbohydrate response element-binding protein gene expression in 3T3-L1 adipocytes and rat adipose tissue. Am J Physiol Endocrinol Metab 287: E424-E430.
26. Hepgül G, Tanrikulu S, Unalp HR, Akguner T, Erbil Y, Olgaç V, et al,. (2010). Preventive effect of pentoxifylline on acute radiation damage via antioxidant and anti-inflammatory pathways. Dig Dis Sci 55: 617-625.
27. Igoudjil A, Abbey-Toby A, Begriche K, Grodet A, Chataigner K, Peytavin G, et al,. (2007). High doses of stavudine induce fat wasting and mild liver damage without impairing mitochondrial respiration in mice. Antivir Ther 12: 389-400.
28. Ishii S, Iizuka K, Miller BC, Uyeda K, (2004). Carbohydrate response element binding protein directly promotes lipogenic enzyme gene transcription. Proc Natl Acad Sci U S A 101: 15597-15602.
29. Joseph SB, Laffitte BA, Patel PH, Watson MA, Matsukuma KE, Walczak R, et al,. (2002). Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptors. J Biol Chem 277: 11019-11025.
30. Kellett GL, Brot-Laroche E, Mace OJ, Leturque A, (2008). Sugar absorption in the intestine: the role of GLUT2. Annu Rev Nutr 28: 35-54.
31. Kim SA, Marshall MA, Melman N, Kim HS, Müller CE, Linden J, et al,. (2002). Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions. J Med Chem 45: 2131-2138.
32. Koppe SW, Sahai A, Malladi P, Whitington PF, Green RM, (2004). Pentoxifylline attenuates steatohepatitis induced by the methionine choline deficient diet. J Hepatol 41: 592-598.
33. Lebrec D, Thabut D, Oberti F, Perarnau JM, Condat B, Barraud H, et al,. (2010). Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis. Gastroenterology 138: 1755-1762.
34. Lee YM, Sutedja DS, Wai CT, Dan YY, Aung MO, Zhou L, et al,. (2008a). A randomized controlled pilot study of pentoxifylline in patients with non-alcoholic steatohepatitis (NASH). Hepatol Int 2: 196-201.
35. Lee AH, Scapa EF, Cohen DE, Glimcher LH, (2008b). Regulation of hepatic lipogenesis by the transcription factor XBP1. Science 320: 1492-1496.
36. Lettéron P, Sutton A, Mansouri A, Fromenty B, Pessayre D, (2003). Inhibition of microsomal triglyceride transfer protein: another mechanism for drug-induced steatosis in mice. Hepatology 38: 133-140.
37. Lindström P, (2007). The physiology of obese-hyperglycemic mice [ob/ob mice]. ScientificWorld Journal 7: 666-685.
38. Marsman HA, van Werven JR, Nederveen AJ, Ten Kate FJ, Heger M, Stoker J, et al,. (2010). Noninvasive quantification of hepatic steatosis in tats using 3.0 T 1H-magnetic resonance spectrosopy. J Magn Reson Imaging 32: 148-154.
39. Navarro-González JF, Jarque A, Muros M, Mora C, García J, (2009). Tumor necrosis factor-α as a therapeutic target for diabetic nephropathy. Cytokine Growth Factor Rev 20: 165-173.
40. Nicklasson M, Björkman S, Roth B, Jönsson M, Höglund P, (2002). Stereoselective metabolism of pentoxifylline in vitro and in vivo in humans. Chirality 14: 643-652.
41. Ohkawa H, Ohishi N, Yagi K, (1979). Assay for lipid peroxides in animal tissues with thiobarbituric acid reaction. Anal Biochem 95: 351-358.
42. Paolisso G, Rizzo MR, Barbieri M, Manzella D, Ragno E, Maugeri D, (2003). Cardiovascular risk in type 2 diabetics and pharmacological regulation of mealtime glucose excursions. Diabetes Metab 29: 335-340.
43. Reagan-Shaw S, Nihal M, Ahmad N, (2007). Dose translation from animal to human studies revisited. FASEB J 22: 659-661.
44. Reymann A, Braun W, Woermann C, (1985). Response of rat small intestinal active aldohexose transport to elevation of mucosal cyclic AMP by forskolin and 3-isobutyl-1-methylxanthine in vitro. Naunyn Schmiedebergs Arch Pharmacol 331: 384-392.
45. Rinella ME, Elias MS, Smolak RR, Fu T, Borensztajn J, Green RM, et al,. (2008). Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet. J Lipid Res 49: 1068-1076.
46. Robin MA, Demeilliers C, Sutton A, Paradis V, Maisonneuve C, Dubois S, et al,. (2005). Alcohol increases tumor necrosis factor α and decreases nuclear factor-κB to activate hepatic apoptosis in genetically obese mice. Hepatology 42: 1280-1290.
47. Satapathy SK, Sakhuja P, Malhotra V, Sharma BC, Sarin SK, (2007). Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol 22: 634-638.
48. Schattenberg JM, Galle PR, (2010). Animal models of non-alcoholic steatohepatitis: of mice and man. Dig Dis 28: 247-254.
49. Scotini E, Carpenedo F, Fassina G, (1983). New derivatives of methyl-xanthines: effect of thiocaffeine, thiotheophylline and 8-phenyltheophylline on lipolysis and on phosphodiesterase activities. Pharmacol Res Commun 15: 131-143.
50. Sharp PA, Debnam ES, (1994). The role of cyclic AMP in the control of sugar transport across the brush-border and basolateral membranes of rat jejunal enterocytes. Exp Physiol 79: 203-214.
51. Stickel F, Seitz HK, (2010). Alcoholic steatohepatitis. Best Pract Res Clin Gastroenterol 24: 683-693.
52. Stoffel M, Duncan SA, (1997). The maturity-onset diabetes of the young (MODY1) transcription factor HNF4alpha regulates expression of genes required for glucose transport and metabolism. Proc Natl Acad Sci U S A 94: 13209-13214.
53. Taha H, Grochot-Przeczek A, Was H, Kotlinowski J, Kozakowska M, Marek A, et al,. (2009). Modulation of inflammatory response by pentoxifylline is independent of heme oxygenase-1 pathway. J Physiol Pharmacol 60: 3-12.
54. Uyeda K, Repa JJ, (2006). Carbohydrate response element binding protein, ChREBP, a transcription factor coupling hepatic glucose utilization and lipid synthesis. Cell Metab 4: 107-110.
55. Vergès B, (2002). The impact of prandial glucose regulation in practice. Diabetes Nutr Metab 15 (6 Suppl): 28-32.
56. Windmeier C, Gressner AM, (1997). Pharmacological aspects of pentoxifylline with emphasis on its inhibitory actions on hepatic fibrogenesis. Gen Pharmacol 29: 181-196.
57. Wright EM, Martín MG, Turk E, (2003). Intestinal absorption in health and disease-sugars. Best Pract Res Clin Gastroenterol 17: 943-956.
58. Zhou D, Brown SA, Yu T, Chen G, Barve S, Kang BC, et al,. (1999). A high dose of ionizing radiation induces tissue-specific activation of nuclear factor-κB in vivo. Radiat Res 151: 703-709.